Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Código QR

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Campbell RK, Neumiller J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Keywords: incretin analog incretin effect liraglutide victoza Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5e09cbf896884ef599e1aa2aec7e23ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Joshua J Neumiller, et al.
Publicado: (2010)

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
por: Sikirica MV, et al.
Publicado: (2017)

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day
por: Igor A. Sklyanik, et al.
Publicado: (2021)

Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study
por: Muo IM, et al.
Publicado: (2019)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed J, et al.
Publicado: (2021)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010)

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
por: Li Z, et al.
Publicado: (2019)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz S
Publicado: (2010)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019)

Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology
por: Guo Q, et al.
Publicado: (2021)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker W, et al.
Publicado: (2021)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney H, et al.
Publicado: (2017)

Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway
por: Liu H, et al.
Publicado: (2020)

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
por: Yang P, et al.
Publicado: (2019)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
por: Cheng F, et al.
Publicado: (2019)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato M, et al.
Publicado: (2014)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
por: Thuillier P, et al.
Publicado: (2015)

Ileal transposition in surgical treatment for type 2 diabetes mellitus
por: Oleg Viktorovich Kornyushin, et al.
Publicado: (2015)

Evaluation of the Association of CGM Metrics with Antihyperglycemic Drugs in Insulin-Treated Diabetics
por: Toshiyuki Horiuchi, et al.
Publicado: (2021)

New prospects in the treatment of diabetes mellitus
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Jean-Pierre Le Floch
Publicado: (2010)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holl, et al.
Publicado: (2014)

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
por: AlMaatouq MA
Publicado: (2012)

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
por: Al Sifri S
Publicado: (2012)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
por: Nishio S, et al.
Publicado: (2015)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

New indications for exenatide therapy of type 2 diabetes mellitus
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2010)

Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
por: Wharton S, et al.
Publicado: (2017)

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
por: Perna S, et al.
Publicado: (2018)

Incretins in the Therapy of Diabetic Kidney Disease
por: Agnieszka Przezak, et al.
Publicado: (2021)

Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
por: Aziz KMA
Publicado: (2015)

Inсretin-based therapy in patients with type 2 diabetes and chronic kidney disease
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)